Terms: = Breast cancer AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2 AND Treatment
14 results:
1. Estimating the risk and benefit of radiation therapy in (y)pN1 stage breast cancer patients: A Bayesian network model incorporating expert knowledge (KROG 22-13).
Jang BS; Chun SJ; Choi HS; Chang JH; Shin KH;
Comput Methods Programs Biomed; 2024 Mar; 245():108049. PubMed ID: 38295597
[TBL] [Abstract] [Full Text] [Related]
2. Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer.
Gao H; Ouyang D; Guan X; Xu J; Chen Q; Zeng L; Pang J; Zou Q; Qian K; Yi W
BMC Cancer; 2024 Jan; 24(1):50. PubMed ID: 38195475
[TBL] [Abstract] [Full Text] [Related]
3. Direct cd32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.
Sconocchia G; Lanzilli G; Cesarini V; Silvestris DA; Rezvani K; Arriga R; Caratelli S; Chen K; Dou J; Cenciarelli C; Toietta G; Baldari S; Sconocchia T; De Paolis F; Aureli A; Iezzi G; Irno Consalvo M; Buccisano F; Del Principe MI; Maurillo L; Venditti A; Ottaviani A; Spagnoli GC
Life Sci Alliance; 2022 Dec; 5(12):. PubMed ID: 36241426
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma.
Birts CN; Savva C; Laversin SA; Lefas A; Krishnan J; Schapira A; Ashton-Key M; Crispin M; Johnson PWM; Blaydes JP; Copson E; Cutress RI; Beers SA
Sci Rep; 2022 May; 12(1):7802. PubMed ID: 35610242
[TBL] [Abstract] [Full Text] [Related]
5. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
[TBL] [Abstract] [Full Text] [Related]
6. Margetuximab: First Approval.
Markham A
Drugs; 2021 Apr; 81(5):599-604. PubMed ID: 33761116
[TBL] [Abstract] [Full Text] [Related]
7. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic breast cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract] [Full Text] [Related]
8. Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.
Hertz DL; Rae JM
Clin Cancer Res; 2016 Jul; 22(13):3121-3. PubMed ID: 27012810
[TBL] [Abstract] [Full Text] [Related]
9. Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early breast cancer.
Varadan V; Gilmore H; Miskimen KL; Tuck D; Parsai S; Awadallah A; Krop IE; Winer EP; Bossuyt V; Somlo G; Abu-Khalaf MM; Fenton MA; Sikov W; Harris LN
Clin Cancer Res; 2016 Jul; 22(13):3249-59. PubMed ID: 26842237
[TBL] [Abstract] [Full Text] [Related]
10. Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.
Norton N; Olson RM; Pegram M; Tenner K; Ballman KV; Clynes R; Knutson KL; Perez EA
Cancer Immunol Res; 2014 Oct; 2(10):962-9. PubMed ID: 24989892
[TBL] [Abstract] [Full Text] [Related]
11. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.
Petricevic B; Laengle J; Singer J; Sachet M; Fazekas J; Steger G; Bartsch R; Jensen-Jarolim E; Bergmann M
J Transl Med; 2013 Dec; 11():307. PubMed ID: 24330813
[TBL] [Abstract] [Full Text] [Related]
12. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.
Muallaoglu S; Disel U; Mertsoylu H; Besen A; Karadeniz C; Taner Sumbul A; Abali H; Ozyilkan O
J BUON; 2013; 18(1):261-7. PubMed ID: 23613414
[TBL] [Abstract] [Full Text] [Related]
13. Biological & physiological aspects of action of insulin-like growth factor peptide family.
Pavelić J; Matijević T; Knezević J
Indian J Med Res; 2007 Apr; 125(4):511-22. PubMed ID: 17598937
[TBL] [Abstract] [Full Text] [Related]
14. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract] [Full Text] [Related]